TY - JOUR
T1 - Stem cell therapy for cerebral ischemia
T2 - From basic science to clinical applications
AU - Abe, Koji
AU - Yamashita, Toru
AU - Takizawa, Shunya
AU - Kuroda, Satoshi
AU - Kinouchi, Hiroyuki
AU - Kawahara, Nobutaka
PY - 2012/7
Y1 - 2012/7
N2 - Recent stem cell technology provides a strong therapeutic potential not only for acute ischemic stroke but also for chronic progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis with neuroregenerative neural cell replenishment and replacement. In addition to resident neural stem cell activation in the brain by neurotrophic factors, bone marrow stem cells (BMSCs) can be mobilized by granulocyte-colony stimulating factor for homing into the brain for both neurorepair and neuroregeneration in acute stroke and neurodegenerative diseases in both basic science and clinical settings. Exogenous stem cell transplantation is also emerging into a clinical scene from bench side experiments. Early clinical trials of intravenous transplantation of autologous BMSCs are showing safe and effective results in stroke patients. Further basic sciences of stem cell therapy on a neurovascular unit and neuroregeneration, and further clinical advancements on scaffold technology for supporting stem cells and stem cell tracking technology such as magnetic resonance imaging, single photon emission tomography or optical imaging with near-infrared could allow stem cell therapy to be applied in daily clinical applications in the near future.
AB - Recent stem cell technology provides a strong therapeutic potential not only for acute ischemic stroke but also for chronic progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis with neuroregenerative neural cell replenishment and replacement. In addition to resident neural stem cell activation in the brain by neurotrophic factors, bone marrow stem cells (BMSCs) can be mobilized by granulocyte-colony stimulating factor for homing into the brain for both neurorepair and neuroregeneration in acute stroke and neurodegenerative diseases in both basic science and clinical settings. Exogenous stem cell transplantation is also emerging into a clinical scene from bench side experiments. Early clinical trials of intravenous transplantation of autologous BMSCs are showing safe and effective results in stroke patients. Further basic sciences of stem cell therapy on a neurovascular unit and neuroregeneration, and further clinical advancements on scaffold technology for supporting stem cells and stem cell tracking technology such as magnetic resonance imaging, single photon emission tomography or optical imaging with near-infrared could allow stem cell therapy to be applied in daily clinical applications in the near future.
KW - Cerebral ischemia
KW - neuroregeneration
KW - neurorepair
KW - stem cell therapy
UR - http://www.scopus.com/inward/record.url?scp=84863430857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863430857&partnerID=8YFLogxK
U2 - 10.1038/jcbfm.2011.187
DO - 10.1038/jcbfm.2011.187
M3 - Review article
C2 - 22252239
AN - SCOPUS:84863430857
SN - 0271-678X
VL - 32
SP - 1317
EP - 1331
JO - Journal of Cerebral Blood Flow and Metabolism
JF - Journal of Cerebral Blood Flow and Metabolism
IS - 7
ER -